FDA extends decision on Aldeyra's dry eye disease drug

The FDA extended its review of Aldeyra Therapeutics' dry eye disease drug reproxalap, after rejecting it twice before, to a new action date of March 16. Aldeyra's stock {$ALDX} was down ...